Skip to main content
SpringerLink
Log in

Pharmacology and toxicology of COX-2 inhibitors

  • Chapter
COX-2 Inhibitors

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 402 Accesses

Abstract

The pharmacological premise upon which the prostaglandin G/H synthase II (PGHS-II) or cyclo-oxygenase-2 (COX-2) inhibitors was developed was essentially that founded in the identification of two different genes coding for the cyclo-oxygenases-1 and -2 [1–3]. COX-1 is considered to be a constitutive enzyme that is responsible for “housekeeping” or physiological functions (e.g., some gastrointestinal (GI) mucosal, renal and haemostatic functions and protective effects) while COX-2, which is induced by inflammatory stimuli, is considered to be important in inflammation, pain and fever [1–5]. Comprehensive reviews on the regulation and roles of these two isoenzymes in inflammation are found in [1–9] and Figure 1 summarizes their essential features.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith WM, Meade EA, De Witt DL (1994) Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 755: 50–57

    Article  Google Scholar 

  2. Vane JR, Botting, RM (1995) A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). In: B Samuelsson et al (eds): Advances in Prostaglandin, Thromboxane and Leukotriene Research, Volume 23 . Raven Press Ltd., New York, 41–48

    Google Scholar 

  3. Vane JR, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44: 1–10

    Article  PubMed  CAS  Google Scholar 

  4. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van de Putte LBA, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073

    PubMed  CAS  Google Scholar 

  5. Kam PCA, See AU-L (2000) Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55: 442–449

    Article  PubMed  CAS  Google Scholar 

  6. Jouzeau J-Y, Terlain B, Abid A, Nédélec E, Netter P (1997) Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53: 563–582

    Article  PubMed  CAS  Google Scholar 

  7. Kulkarni SK, Jain NK, Singh A (2000) Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Findings Exp Clin Pharmacol 22: 291–298

    Article  CAS  Google Scholar 

  8. Vane J, Botting J, Botting R (eds) (1995) Improved non-steroid anti-inflammatory drugs COX-2 enzyme inhibitors. Kluwer Academic Publishers, Dordrecht and William Harvey Press, London

    Google Scholar 

  9. Vane J, Botting RM (eds): (2001) Therapeutic roles of selective COX-2 inhibitors. William Harvey Press, London

    Google Scholar 

  10. Fenner H (1997) Differentiating among nonsteroidal anti-inflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Semin Arthritis Rheum 26: 28–33

    Article  PubMed  CAS  Google Scholar 

  11. Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M et al (1999) Interpreting the clinical significance of the differential inhibition of cyclooxygenase-2 and cyclooxygenase-2. Rheumatology 38: 779–788

    Article  PubMed  CAS  Google Scholar 

  12. Fitzgerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433–442

    Article  PubMed  CAS  Google Scholar 

  13. Herbette LF, Vecchiarelli, Trummlitz G (1996) NSAID mechanism of action: the role of intracellular pharmacokinetics. In: J Vane, J Botting, R Botting (eds): Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors. Kluwer Academic Publishers, Dordrecht, William Harvey Press London, 85–102

    Google Scholar 

  14. Trummlitz G, van Ryn J (2002) Designing selective COX-2 inhibitors: molecular modelling approaches. Curr Opin Drug Discovery Development 5: 550–561

    CAS  Google Scholar 

  15. Chulada PC, Langenbach R (1997) Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs suing exogenous and endogenous sources of arachidonic acid. J Pharmacol Exp Ther 280: 606–613

    PubMed  CAS  Google Scholar 

  16. Hulkower KI, Otis ER, Wernimont AK, Bell RL (1997) Stimulus dependence of non-steroidal anti-inflammatory drug potency in a cellular assay of prostaglandin H synthase-2. Eur J Pharmacol 331: 79–85

    Article  PubMed  CAS  Google Scholar 

  17. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563–7568

    Article  PubMed  CAS  Google Scholar 

  18. Warner TD, Pairet M, Van Ryn J (2001) Test systems for inhibitors of cyclooxygenase-1 and cyclooxygenase-2. In: JR Vane, RM Botting (eds): Therapeutic roles of selective COX-2 inhibitors. William Harvey Press, London, 76–94

    Google Scholar 

  19. Sanda M, Jacob GB, Fliedner Jt L, Kennedy J, Gotz M (1987) Etodolac. In: AJ Lewis, DE Furst DE (eds): Nonsteroidal Anti-inflammatory Drugs Mechanisms and Use. Marcel Dekker Inc, New York, 349–370

    Google Scholar 

  20. Jones R (2001) Etodolac: Clinical profile of an established cyclooxygenase-2 inhibitor. In: JR Vane, RM Botting (eds): Therapeutic Roles of Selective COX-2 inhibitors. William Harvey Press, London, 482–497

    Google Scholar 

  21. Glaser KB (1995) Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharmacology 3: 335–345

    Article  CAS  Google Scholar 

  22. Dvornik D, Lee DKH (1989) Theoretical mechanism for the gastrointestinal safety of etorolac: selective sparing of cytoprotective prostaglandins. Clin Rheumatol 8 (Suppl. 1): 16–24

    Article  PubMed  Google Scholar 

  23. Denurson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C (1983) Resolution of etodolac and anti-inflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 26: 1778–1780

    Article  Google Scholar 

  24. Rainsford KD (1999) Pharmacology and toxicology of ibuprofen. In: KD Rainsford (ed.): Ibuprofen: A Critical Bibliographic Review. Taylor and Francis, London, 143–275

    Chapter  Google Scholar 

  25. Rainsford KD (1995) Gastric ulcerogenicity in mice of enantiomers of non-steroidal anti-inflammatory drugs having differing potency as prostaglandin synthesis inhibitors. Pharmaceutical Sci 1: 169–171

    CAS  Google Scholar 

  26. Ogiso T, Kitagawa T, Iwaki M, Tanino T (1997) Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics. Biol Pharm Bull 20: 405–410

    Article  PubMed  CAS  Google Scholar 

  27. Strickmann DB, Blaschke G (2001) Isolation of an unknown metabolite of the non-steroidal anti-inflammatory drug etodolac and its identification as 5-hydroxy etodolac. J Pharmaceutical Biomedical Analysis 25: 977–984

    Article  CAS  Google Scholar 

  28. Brocks DR, Jamali F (1990) The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. Drug Metabolism Disp 18: 471–475

    CAS  Google Scholar 

  29. Laudanno OM, Cesolari JA, Esnarriaga J, Flaherty P, Vada J, Guastalli G, San Miguel P, Bedini OA (1998) In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats. Acta Gastroenterol Latinoam 28: 249–255

    PubMed  CAS  Google Scholar 

  30. Reimer ME, Johnston SA, Leib MS, Duncan RB Jr, Reimer DC, Marini M, Gimber TK (1999) The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med 13: 472–477

    Article  PubMed  CAS  Google Scholar 

  31. Laudanno OM, Cesolarij JA, Esnarriaga J, San Miguel P, Bedini OA (2000) In vivo selectivity of nonsteroidal anti-inflammatory drugs and gastrointestinal ulcers in rats. Dig Dis Sci 45: 1359–1365

    CAS  Google Scholar 

  32. Wilcox GM, Porensky RS (1997) Acute colitis associated with etodolac. J Clin Gastroenterol 25: 367–368

    Article  PubMed  CAS  Google Scholar 

  33. Eis MJ, Watkins BM, Philip A, Welling RE (1998) Nonsteroidal-induced benign strictures of the colon: a case report and review of the literature. Am J Gastroenterol 93: 120–121

    Article  PubMed  CAS  Google Scholar 

  34. Gopal DV, Katon RM (1999) Endoscopic balloon dilation of multiple NSAID-induced colonic strictures: case report and review of literature on NSAID-related colopathy. Gastrointest Endosc 50: 120–123

    Article  PubMed  CAS  Google Scholar 

  35. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ (1987) Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 93: 480–489

    PubMed  CAS  Google Scholar 

  36. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS (1993) Side-effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104: 1832–1847

    PubMed  CAS  Google Scholar 

  37. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB (2000) A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 56: 383–388

    Article  PubMed  CAS  Google Scholar 

  38. Boni JP, Korth-Bradley JM, Martin P, Simcoe DK, Richards LS, Rennebohm R, Walson PD (1999) Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis. Clin Ther 21: 1715–1724

    Article  PubMed  CAS  Google Scholar 

  39. Rothstein R (1998) Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 105 (5A): 39S–43S

    Article  PubMed  CAS  Google Scholar 

  40. Russell RI (1999) Defining patients at risk of non-steroidal anti-inflamamtory drug gastropathy. Ital J Gastroenterol Hepatol 31:S14–S18

    PubMed  Google Scholar 

  41. Neustadt DH (1997) The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 11: 907–912

    Article  Google Scholar 

  42. Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N (2003) NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 17: 321–332

    Article  PubMed  CAS  Google Scholar 

  43. Wilcox GM, Porensky RS (1997) Acute colitis associated with etodolac. J Clin Gastroenterol 25: 367–368

    Article  PubMed  CAS  Google Scholar 

  44. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y (1998) Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-infalmamtory drugs using human platelets and synovial cells. Eur J Pharmacol 347: 87–94

    Article  PubMed  CAS  Google Scholar 

  45. Lipscomb GR, Wallis N, Armstrong G, Goodman MJ, Rees WD (1995) Gastric mucosal adaptation to etodolac and naproxen. Aliment Pharmacol Ther 9: 379–385

    Article  PubMed  CAS  Google Scholar 

  46. Lipscomb GR, Campbell F, Rees WD (1997) The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 11: 907–912

    Article  PubMed  CAS  Google Scholar 

  47. Kusuhara H, Komatsu H, Sumichika H, Sugahara K (1999) Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. Eur J Pharmacol 383: 331–337

    Article  PubMed  CAS  Google Scholar 

  48. Noda M, Tasumi Y, Tomizawa M, Takama T, Mitsufuji S, Sugihara H, Kashima K, Hattori T (2002) Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. J Gasdtroenterol 37: 896–904

    Article  CAS  Google Scholar 

  49. Kusunoki N, Yamazaki R, Kawai S (2002) Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhbitors. Arthritis Rheum 46: 3159–3167

    Article  PubMed  CAS  Google Scholar 

  50. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S (2002) Selective cycloxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278–284

    Article  PubMed  CAS  Google Scholar 

  51. Sato TA, Keelan JA, Blumenstein M, Mitchell MD (2002) Efficacy and specificity of non-steroidal anti-inflammatory drugs for the inhibition of cytokine-stimulated prostaglandin E(2) secretion by amnion-derived WISH cells. Prostaglandins Leukotrienes Essential Fatty Acids 66: 525–527

    Article  CAS  Google Scholar 

  52. Sato TA, Keelan JA, Mitchell MD (2002) Regulation of prostaglandin production in an immortalized human myometrial cell line by cytokines and non-steroidal anti-inflammatory drugs. Eur J Obstet Gynecol Reprod Biol 100: 158–162

    Article  PubMed  CAS  Google Scholar 

  53. Takahashi M, Katayama Y, Takada H, Kuwayama H, Terano A (2000) The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther 14: 44–49

    Article  PubMed  CAS  Google Scholar 

  54. Lain L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM (1995) Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 9: 127–135

    Article  Google Scholar 

  55. Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kawasaki H, Hasegawa J (2000) Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 47: 812–819

    Article  PubMed  CAS  Google Scholar 

  56. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. In J Cancer 91: 894–899

    CAS  Google Scholar 

  57. Kamijo T, Sato T, Nagatomi Y, Kitamura T (2001) Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 8: S35–S39

    Article  PubMed  Google Scholar 

  58. Endo K, Sairyo K, Komatsubara S, Sasa T, Egawa H, Yonekura D, Adachi K, Ogawa T, Murakami R, Yasui N (2002) Cyclooxygenase-2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 21: 235–238

    Article  PubMed  Google Scholar 

  59. Kopp UC, Cicha MZ, Smith LA, Haeggstrom JZ, Samuelsson B, Hokfelt T (2000) Cyclooxygenase-2 involved in stimulation of renal mechanosensitive neurons. Hypertension 35: 373–378

    Article  PubMed  CAS  Google Scholar 

  60. Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ (1995) Fulminant hepatic failure associated with etodolac use. Am J Gastroenterol 90: 659–661

    PubMed  CAS  Google Scholar 

  61. Degner F, Richardson B (2001) Review of gastrointestinal tolerability and safety of meloxicam. Inflammopharmacology 9: 71–80

    Article  CAS  Google Scholar 

  62. Degner F, Lanes S, van Ryn J, Sigmund R (2001) Pharmacological and clinical profile of meloxicam. In: JR Vane, RM Botting (eds): Therapeutic roles of selective COX-2 inhibitors. William Harvey Press, London, 498–523

    Google Scholar 

  63. Van Bree H, Justus C, Quirke JF (1994) Preliminary observations on the effects of meloxicam in a new model for acute intra-articular inflammation in dogs. Vet Res Commun 18: 217–224

    Article  PubMed  Google Scholar 

  64. Rainsford KD, Skerry TM, Chindemi P, Delaney K (1999) Effects of the NSAIDs meloxicam and indomethacin on cartilage proteoglycan synthesis and joint responses to calcium pyrophosphate crystals in dogs. Vet Res Commun 23: 101–113

    Article  PubMed  CAS  Google Scholar 

  65. Stei P, Kruss B, Wiegleb J, Trach V (1996) Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Brit J Rheumatol 35: 44–50

    Article  CAS  Google Scholar 

  66. Ghozlan PR, Bernhardt M, Velicitat P, Bluhmki E (1996) Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Brit J Rheumatol 35: 51–55

    Article  CAS  Google Scholar 

  67. Engelhardt G (1996) Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Brit J Rheumatol 35: 4–12

    Article  CAS  Google Scholar 

  68. Trummlitz G, Engelhardt G (1987) Meloxicam: Structural aspects of a new NSAID with improved therapeutic properties. Poster presented at the XIth European Congress of Rheumatology, Athens, 28 June to 4 July 1987

    Google Scholar 

  69. Lehmann HA, Baumeister M, Lützen L, Wiegleb J (1996) Meloxicam: a toxicology overview. Inflammopharmacology 4: 105–123

    Article  CAS  Google Scholar 

  70. Luger P, Daneck K, Engel W, Trummlitz G, Wagner (1996) Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci 4: 175–187

    Article  CAS  Google Scholar 

  71. Schoenfeld P (1999) Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomised controlled trials. Am J Med 107 (6A): 48S–54S

    Article  PubMed  CAS  Google Scholar 

  72. McCormack K (1982) Mathematical model for assessing risk of gastrointestinal reactions to NSAIDs. In: KD Rainsford (ed.): Azapropazone - 20 years of clinical use . Kluwer Academic Publishers, London, 81–93

    Google Scholar 

  73. Rainsford KD (1999) Profile and mechanisms of gastrointestinal and other side-effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107 (6A): 27S–36S

    Article  PubMed  CAS  Google Scholar 

  74. Engelhardt G, Homma D, Schnitzler C (1995) Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 44: 548–555

    Article  PubMed  CAS  Google Scholar 

  75. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M (1995) Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 23: 1206–1213

    PubMed  CAS  Google Scholar 

  76. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T (1998) Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 28: 1–13

    Article  PubMed  CAS  Google Scholar 

  77. US Food and Drug Administration (2002) MELOXICAM, MOBICTMTablets, 7.5 mg. Boehringer-Ingelheim Pharmaceuticals Inc (Sponsor). New Drug Application - NDA 20–938

    Google Scholar 

  78. Schmid J, Busch U, Trummlitz G, Prox A, Kaschke S, Wachsmuth H (1995) Meloxicam: Metabolic profile and biotransformation products in the rat. Xenobiotica 25: 1219–1236

    Article  PubMed  CAS  Google Scholar 

  79. Turck D, Roth W, Busch U (1998) A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35 (Suppl 1): 13–16

    Article  Google Scholar 

  80. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W (1998) Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 26: 576–584

    PubMed  CAS  Google Scholar 

  81. Busch U, Engelhardt G (1990) Distribution of (14C) meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 16: 49–52

    PubMed  CAS  Google Scholar 

  82. Ludwig E, Schmid J, Beschke K, Ebner T (1999) Activation of human cytochrome P-450 3A4catalyzed meloxicam 5’-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 290: 1–8

    CAS  Google Scholar 

  83. Xu HY, Zhong DF, Zhao LM, Zhang YF, Zhang BJ (2001) Pharmacokinetics of meloxicam in healthy Chinese volunteers. Yao Xue Xue Bao 36: 71–73

    PubMed  CAS  Google Scholar 

  84. Lapicque F, Vergne P, Jouzeau JY, Loeuille D, Gillet P, Vignon E, Thomas P, Velicitat P, Turck D, Guillaume C et al (2000) Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 39: 369–382

    Article  PubMed  CAS  Google Scholar 

  85. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G (1998) Differential inhibi-tion of cyclooxygenases-1 and -2 by meloxicam and its 4’-isomer. Inflamm Res 47: 270–276

    Article  PubMed  CAS  Google Scholar 

  86. Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, Tillement JP (1997) Bloodto-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 14: 650–656

    Article  PubMed  CAS  Google Scholar 

  87. Poulsen Nautrup B, Horstermann D (1999) Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs. Dtsch Tierarztl Wochenschr 106: 94–100

    Google Scholar 

  88. Lees P, Sedgwick AD, Higgins AJ, Pugh KE, Busch U (1991) Pharmacodynamics and pharmacokinetics of meloxicam in the horse. Brit Vet J 147: 97–108

    Article  CAS  Google Scholar 

  89. Yabe T, Honma M, Katsuki S, Wiegleb J, Luetzen L, Pueschner H, Lehmann H (1997) Single and repeated dose toxicity studies of meloxicam by oral administration in minipigs. Pharmacometrics 53: 197–212

    CAS  Google Scholar 

  90. Baert K, De Backer P (2003) Comparative pharmacokinetics of three non-steroidal anti-inflammatory drugs in five bird species. Comp Biochem Physiol C Toxicol Pharmacol 134: 25–33

    Article  PubMed  CAS  Google Scholar 

  91. US Food and Drug Administration (2000) New Animal Drug Application NADA 141–213. Metacam®(meloxicam) 0.5 mg/mL and 1.5 mg/mL Oral Suspension “indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Boehringer Ingelheim Vetmedica, Inc. (Sponsor). Approval date April 15 2003

    Google Scholar 

  92. Euller-Ziegler L, Velicitat P, Bluhmki E, Türck D, Scheuerer S, Combe B (2001) Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 50 (Suppl 1): S5–S9

    PubMed  CAS  Google Scholar 

  93. Engelhardt G, Boegel R, Schnitzer C, Utzmann R (1996) Meloxicam: influence on arachidonic acid metabolism, part I. In vitro findings. Biochem Pharmacol 51: 21–28

    Article  PubMed  CAS  Google Scholar 

  94. Engelhardt G, Boegel R, Schnitzer C, Utzmann R (1996) Meloxicam: influence on arachidonic acid metabolism, part II. In vivo findings. Biochem Pharmacol 51: 29–38

    Article  PubMed  CAS  Google Scholar 

  95. Ogino K, Hatanaka K, Kawamura M, Ohno T, Harada Y (2000) Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Pharmacology 61: 244–250

    Article  PubMed  CAS  Google Scholar 

  96. Rainsford KD, Ginsburg I, Gadd SJ (1997) A comparison between the effects of meloxicam and other NSAIDs on the production of oxyradicals by human polymorphonuclear leucocytes. Immunopharmacology 5: 9–19

    CAS  Google Scholar 

  97. Saleh TS, Calixto JB, Medeiros YS (1999) Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides 20: 949–956

    Article  PubMed  CAS  Google Scholar 

  98. Agha AM, El-Khatib AS, Al-Zuhair H (1999) Modulation of oxidant status by meloxicam in experimentally induced arthritis. Pharmacol Res 40: 385–392

    Article  PubMed  CAS  Google Scholar 

  99. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Stachura J, Pajdo R, Hahn EG (1999) Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol 385: 47–61

    Article  PubMed  CAS  Google Scholar 

  100. Brzozowski T, Konturek PC, Konturek SJ, Drozdowicz D, Pajdo R, Pawlik M (2000) Expression of cyclooxygenase (COX-1 and COX-2) in adaptive cytoprotection induced by mild stress. J Physiol Paris 94: 83–91

    Article  PubMed  CAS  Google Scholar 

  101. Villegas I, Martin MJ, La Casa C, Motilva V, Alarcon de la Lastra C (2000) Effects of meloxicam on oxygen radical generation in rat gastric mucosa. Inflamm Res 49: 361–366

    Article  PubMed  CAS  Google Scholar 

  102. Villegas I, Martin MJ, La Casa C, Motilva V, De La Lastra CA (2002) Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study. Free Radic Res 36: 769–777

    Article  PubMed  CAS  Google Scholar 

  103. Frode-Saleh TS, Calixto JB (2000) Synergistic anti-inflammatory effect of NfkappaB inhibitors and steroidal or non-steroidal anti-inflammatory drugs in the pleural inflammation induced by carrageenan in mice. Inflamm Res 49: 330–337

    Article  PubMed  CAS  Google Scholar 

  104. Bednarek D, Szuster-Ciesielska A, Zdzisinska B, Kondracki M, Paduch R, Kandefer-Szerszen M (1999) The effect of steroidal and non-steroidal anti-inflammatory drugs on the cellular immunity of calves with experimentally-induced local lung inflammation. Vet Immunol Immunopathol 71: 1–15

    Article  PubMed  CAS  Google Scholar 

  105. Lopez-Armada MJ, Sanchez-Pernaute O, Largo R, Diez-Ortego I, Palacios I, Egido J, HereroBeaumont G (2002) Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. Ann Rheum Dis 61: 1027–1030

    Article  PubMed  CAS  Google Scholar 

  106. Rainsford KD, Ying C, Smith FC (1997) Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. J Pharm Pharmacol 49: 991–998

    Article  PubMed  CAS  Google Scholar 

  107. Bonta IL, Elliott GR (1992) Non-steroidal anti-inflammtory drugs and the augmented lipoxygenase pathway: conceivable impact on joint conditions. In: KD Rainsford, GP Velo (eds): Side-effects of Non-inflammatory Drugs 3. Kluwer Academic Publishers, Dordrecht, 269–274

    Chapter  Google Scholar 

  108. Rainsford KD (2003) Cytokines and eicosanoids in arthritis. In: P.B. Curtis-Prior (ed.): Eicosanoids. Wiley, Chichester, 347–358

    Google Scholar 

  109. Bayliss MT, Roughley PJ (1985) The properties of proteoglycan prepared from human articlular cartilage by using associative cesium chloride gradients of high and low starting densities. Biochem J 232: 111–117

    PubMed  CAS  Google Scholar 

  110. Konigsson K, Odensvik K, Kindahl H (2002) Endocrine, metabolic and clinical effects of intravenous endotoxin injection after pre-treatment with meloxicam in heifers. J Vet Med A Physiol Pathol Clin Med 49: 408–414

    Article  PubMed  CAS  Google Scholar 

  111. Roth J, Hubschle T, Pehl U, Ross G, Gerstberger R (2002) Influence of systemic treatment with cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of cytokines and cortisol in guinea-pigs. Pflugers Arch 443: 411–417

    Article  PubMed  CAS  Google Scholar 

  112. Aguirre-Banuelos P, Granados-Soto V (2000) Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive action of meloxicam in the formalin test. Eur J Pharmacol 395: 9–13

    Article  PubMed  CAS  Google Scholar 

  113. Laird JM, Carter AJ, Grauert M, Cervero F (2001) Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 134: 1742–1748

    Article  PubMed  CAS  Google Scholar 

  114. Chidiac JJ, Rifai K, Hawwa NN, Massaad CA, Jurjus AR, Jabbur SJ, Saade NE (2002) Nociceptive behaviour induced by dental application of irritants to rat incisors: a new model for tooth inflammatory pain. Eur J Pain 6: 55–67

    Article  PubMed  Google Scholar 

  115. Jain NK, Kulkarni SK, Singh A (2002) Modulation of NSAID-induced antinociceptive and ant-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci 70: 2857–2869

    Article  PubMed  CAS  Google Scholar 

  116. Doig PA, Purbrick KA, Hare JE, McKeown DB (2000) Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 41: 296–300

    PubMed  CAS  Google Scholar 

  117. Moreau M, Dupuis J, Bonneau NH, Desnoyers M (2003) Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec 152: 323–329

    Article  PubMed  CAS  Google Scholar 

  118. Mathews KA, Pettifer G, Foster R, McDonell W (2001) Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. Am J Vet Res 62: 882–888

    Article  PubMed  CAS  Google Scholar 

  119. Lascelles BD, Henderson AJ, Hackett IJ (2001) Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. J Small Anim Pract 42: 587–593

    Article  PubMed  CAS  Google Scholar 

  120. Nell T, Bergman J, Hoeijmakers M, Van Laar P, Horspool LJ (2002) Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation. J Small Anim Pract 43: 208–212

    Article  PubMed  CAS  Google Scholar 

  121. Slingsby LS, Waterman-Earson AE (2002) Comparison between meloxicam and carprofen for postoperative analgesia after feline ovariohysterectomy. J Small Anim Pract 43: 286–289

    Article  PubMed  CAS  Google Scholar 

  122. Reyes L, Tinworth KD, Li KM, Yau DF, Waters KA (2002) Observer-blinded comparison of two nonopioid analgesics for postoperative pain in piglets. Pharmacol Biochem Behav 73: 521–528

    Article  PubMed  CAS  Google Scholar 

  123. Budsberg SC, Cross AR, Quandt JE, Pablo LS, Runk AR (2002) Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs. Am J Vet Res 63: 1557–1563

    Article  PubMed  CAS  Google Scholar 

  124. Singsby LS, Waterman-Pearson AE (2000) Postoperative analgesia in the cat after ovariohysterectomy by use of carprofen, ketoprofen, meloxicam or tolfenamic acid. J Small Anim Pract 41: 447–450

    Article  Google Scholar 

  125. Din C (2002) Do NSAIDs affect the progression of osteoarthritis? Inflammation 26: 139–142

    Article  Google Scholar 

  126. Sadowski T, Steinmeyer J (2001) Effects of non-steroidal anti-inflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 9: 407–415

    Article  PubMed  CAS  Google Scholar 

  127. Lin SK, Kok SH, Kuo MY, Wang TJ, Wang JT, Yeh FT, Hsiao M, Lan WH, Hong CY (2002) Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats. Eur J Oral Sci 110: 246–253

    Article  PubMed  CAS  Google Scholar 

  128. Bezerra MM, de Lima V, Alencar VB (2000) In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 61: 802–810

    Google Scholar 

  129. Gomez-Gaviro MV, Gonzalez-Alvaro I, Dominguez-Jimenez C, Peschon J, Black RA, Sanchez-Madrid F, Diaz-Gonzalez F (2002) Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem 277: 38212–38221

    Article  PubMed  CAS  Google Scholar 

  130. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, Silveira LH, Martinez-Lavin M (1999) Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 57: 743–752

    Article  PubMed  CAS  Google Scholar 

  131. Pitcher GM, Henry JL (2001) Meloxicam selectively depresses the after discharge of rat spinal dorsal horn neurones in response to noxious stimulation. Neurosci Lett 305: 45–48

    Article  PubMed  CAS  Google Scholar 

  132. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D, O’Brien PE (2001) Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent. Gut 48: 660–666

    Article  PubMed  CAS  Google Scholar 

  133. Hussey HJ, Tisdale MJ (2000) Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 87: 95–100

    Article  PubMed  CAS  Google Scholar 

  134. Brown WA, Skinner SA, Malcontenti-Wilson C, Misajon A, DeJong T, Vogiagis D, O’Brien PE (2000) Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formatin but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 15: 1386–1392

    Article  PubMed  CAS  Google Scholar 

  135. Teisman P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 39: 167–174

    Article  Google Scholar 

  136. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16: 438–440

    PubMed  CAS  Google Scholar 

  137. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, Stevens MJ (2002) Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51: 2619–2628

    Article  PubMed  CAS  Google Scholar 

  138. Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I (2002) New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25: 280–282

    Article  PubMed  CAS  Google Scholar 

  139. Mohn C, Lomniczi A, Faletti A, Scorticati C, Elverdin JC, McCann SM, Rettori V (2001) Effects of aminoguanidine and meloxicam on nitric oxide and prostaglandin E production induced by lipopolysaccharide in the hypothalamus and anterior pituitary of the rat. Neuroimmunomodulation 9: 276–285

    Article  PubMed  CAS  Google Scholar 

  140. Gupta YK, Chaudhary G, Sinha K (2002) Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat. Can J Physiol Pharmacol 80: 210–217

    Article  PubMed  CAS  Google Scholar 

  141. Heindl B, Becker BF (2001) Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 363: 233–240

    Article  PubMed  CAS  Google Scholar 

  142. Moya M, Campana V, Gavotto A, Spitale L, Simes J, Palma J (2002) Hyperfibrinogenemia in rats treated with meloxicam. Jpn Heart J 43: 559–566

    Article  PubMed  CAS  Google Scholar 

  143. Arslan S, Erdem S, Sivri A, Hascelik Z, Tan E (2002) Exercise-induced apoptosis of rat skeletal muscle and the effect of meloxicam. Rheumatology International 21: 133–136

    Article  PubMed  CAS  Google Scholar 

  144. Laudanno OM, Cesolari JA, Esnarriaga J, San Miguel P, Bedini OA (2000) In vivo selectivity of nonsteroidal antiinflamamtory drugs and gastrointestinal ulcers in rats. Dig Dis Sci 45: 1359–1365

    Article  PubMed  CAS  Google Scholar 

  145. Villegas I, Alarcon de la Lastra C, La Casa C, Motilva V, Martin MJ (2001) Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and prioxicam in rats. Eur J Pharmacol 414: 79–86

    Article  PubMed  CAS  Google Scholar 

  146. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, Ptak A, Hahn EG (2001) Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microscopy Research and Technique 53: 343–353

    Article  PubMed  CAS  Google Scholar 

  147. Villegas I, Alarcon de la Lastra C, Martin MJ, Motilva V, La Casa Garcia C (2002) Gastric damage induced by subchronic administration of preferential cyclooxgyenase-1 and cyclooxygenase-2 inhibitors in rats. Pharmacology 66: 68–75

    Article  PubMed  CAS  Google Scholar 

  148. Birck R, Krzossok S, Knoll T, Braun C, van Der Woude FJ, Rohmeiss P (2000) Preferential COX-2 inhibitor, meloxicam, compromises renal perfusion in euvolemic and hypovolemic rats. Exp Nephrol 8: 173–180

    Article  PubMed  CAS  Google Scholar 

  149. Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Dequeker J, Isomäki H, Littlejohn G, Mau J et al on behalf of the Melissa Study Group (1998) Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Brit J Rheumatol 37: 937–945

    Article  Google Scholar 

  150. Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Isomaki H, Littlejohn G, Mau J et al on behalf of the Select Study Group (1998) Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evalution of COX-inhibiting therapies (select) trial in osteoarthritis. Brit J Rheumatol 37: 946–951

    Article  Google Scholar 

  151. Layton D, Heeley E, Hughes K, Shakir SAW (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology 42: 622–631

    Article  PubMed  CAS  Google Scholar 

  152. Hawkey CJ (2001) NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist’s perspective. Clin Exp Rheumatol 19 (Suppl 25): S23–S30

    PubMed  CAS  Google Scholar 

  153. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353: 307–314

    Article  PubMed  CAS  Google Scholar 

  154. Ward A, Brogden RN (1988) Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 36: 732–753

    Article  PubMed  CAS  Google Scholar 

  155. Kalgutkar AS (1999) Selective cyclooxygenase-2 inhibitors as non-ulcerogenic anti-inflammatory agents. Exp Opin Ther Patents 9: 831–849

    Article  CAS  Google Scholar 

  156. Singla AK, Chawla M, Singh A (2000) Nimesulide: some pharmaceutical and pharmacological aspects-an update. J Pharm Pharmacol 52: 467–486

    Article  PubMed  CAS  Google Scholar 

  157. Swingle KF, Moore GGI, Grant TJ (1976) 4-nitro-2-phenoxymethanesulfonanilide (R 805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn 221: 132–139

    PubMed  Google Scholar 

  158. Rainsford KD (1996) Mode of action, uses, and side-effects of anti-inflammatory drugs. In: KD Rainsford (ed.): Advances in Anti-Rheumatic Therapy. CRC Press, Boca Raton. 59–111

    Google Scholar 

  159. Bennett A (2001) Nimesulide: A well-established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: JR Vane, RM Botting (eds): Therapeutic roles of selective COX-2 inhibitors. William Harvey Press, London, 524–540

    Google Scholar 

  160. Bennett A, Villa G (2000) Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opinion on Pharmacotherapy 1: 277–286

    Article  PubMed  CAS  Google Scholar 

  161. Bennett A, Berti F, Ferreira SH (eds) (1993) Nimesulide: A Multifactorial Therapeutic Approach to the Inflammatory Process? A 7-year clinical experience. Drugs 46: 1–283

    Google Scholar 

  162. Davis R, Brogden RN (1994) Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48: 431–454

    Article  PubMed  CAS  Google Scholar 

  163. Rabasseda X (1997) Safety profile of nimesulide: ten years of clinical experience. Drugs of Today 33: 1–10

    Article  Google Scholar 

  164. Bernareggi A (1998) Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet 35: 247–274

    Article  PubMed  CAS  Google Scholar 

  165. Rainsford KD (1998) An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury. Inflammopharmacology 6: 203–221

    Article  PubMed  CAS  Google Scholar 

  166. Rainsford KD (2001) Nimesulide: Overview of properties and applications. Drugs of Today 37 (Supp B): 3–7

    CAS  Google Scholar 

  167. Bennett A (2001) Clinical importance of the multifactorial actions of nimesulide. Drugs of Today 37 (Supp B): 9–14

    CAS  Google Scholar 

  168. Fitzgerald D, McCrory C (2001) Pharmacology of COX-2 inhibition in man: anti-inflammatory and analgesic effects of nimesulide. Drugs of Today 37 (Supp B): 15–20

    CAS  Google Scholar 

  169. Huskisson EC (2001) Nimesulide, a balanced drug for the treatment of osteoarthritis. Clin Exp Rheumatol 19 (I): S21–S25

    PubMed  CAS  Google Scholar 

  170. Tavares IA, Borrelli F, Welsh NJ (2001) Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. Clin Exp Rheumatol 19: S13–S15

    PubMed  CAS  Google Scholar 

  171. Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ et al (2001) Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 48: 339–346

    Article  PubMed  CAS  Google Scholar 

  172. Huskisson EC (2001) Nimesulide, a balanced drug for the treatment of osteoarthritis. Clin Exp Rheumatol 19 (Suppl 22): S21–S25

    PubMed  CAS  Google Scholar 

  173. Rainsford KD (1999) Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology 38: 4–10

    Article  PubMed  CAS  Google Scholar 

  174. Wober W (1999) Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology 38: 33–38

    Article  PubMed  CAS  Google Scholar 

  175. Liaropoulos L (1999) Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece. Rheumatology 38: 39–46

    Article  PubMed  CAS  Google Scholar 

  176. Carini M, Aldini G, Stefani R, Marinello C, Facino RM (1998) Mass spectrometric characterization and HPLC determination of the main urinary metabolites of nimesulide in man. J Pharm Biomed Anal 18: 201–211

    Article  PubMed  CAS  Google Scholar 

  177. Boelsterli UA (2002) Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Safety 25: 633–648

    Article  PubMed  CAS  Google Scholar 

  178. Boelsterli UA (2002) Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. Int J Clin Pract Suppl 128: 30–36

    PubMed  CAS  Google Scholar 

  179. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM (2000) Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56: 81–87

    Article  PubMed  CAS  Google Scholar 

  180. Carrasco Portugal MC, Granados Soto V, Camacho Vieyra GA, Parez Urizar J, Flores Murrieta FJ (2000) A simple method for determination of nimesulide in rat blood samples by high perform-ance liquid chromatography. J Liquid Chromatography and Related Technologies 23: 2237–2244

    Article  Google Scholar 

  181. Mukherjee P, Rachita C, Aisen PS, Pasinetti GM (2001) Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 19: S7–S11

    PubMed  CAS  Google Scholar 

  182. Sanchez C, Mateus MM, Defresne MP, Crielaard JM, Reginster JY, Henrotin YE (2002) Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin lbeta and nonsteroidal antiinflamamtory drugs. J Rheumatol 29: 772–782

    PubMed  CAS  Google Scholar 

  183. Rainsford KD, Omar H, Ashraf A, Hewson AT, Bunning RAD, Rishiraj R, Shepherd P, Seabrook RW (2002) Recent pharmacodynamic and pharmacokinetic findings on oxaprozin. Inflammopharmacology 10: 185–239

    Article  CAS  Google Scholar 

  184. Bavbek S, Celik G, Ediger D, Mungan D, Demirel YS, Misirligil Z (1999) The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammtory drug intolerance. J Asthma 36: 657–663

    Article  PubMed  CAS  Google Scholar 

  185. Sanchez-Borges M, Capriles-Hulett A (2000) Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 84: 101–106

    Article  PubMed  CAS  Google Scholar 

  186. Rowlinson SW, Kiefer JR, Prusakiewicz J, Pawlilz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ (2003) A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem Aug 18, 2003, in press

    Google Scholar 

  187. Garcia-Níeto R, Perez C, Checa A, Gago F (1999) Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Rheumatology 38: 14–18

    Article  PubMed  Google Scholar 

  188. Julemont F, de Leval X, Michaux C, Damas J, Charlier C, Durant F, Pirotte B, Dogne JM (2002) Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. J Med Chem 45: 5182–5185

    Article  PubMed  CAS  Google Scholar 

  189. Rufer C, Schillinger E, Böttcher I, Repenthin W, Herrmann Ch (1982) Non-steroidal anti-inflammatories - XII. Biochem Pharmacol 22: 3591–3596

    Article  Google Scholar 

  190. Swingle KF, Bell RL, Moore GGI (1985) Anti-inflammatory activity of antioxidants. In: KD Rainsford (ed.): Anti-Inflammatory and Anti-Rheumatic Drugs. Volume III: Anti-Rheumatic Drugs, Experimental Agents and Clinical Aspects of Drug Use. CRC Press, Boca Raton, 105–126

    Google Scholar 

  191. Orhan H, Dogruer DS, Cakir B, Sahin G, Sahin MF (1999) The in vitro effects of new non-steroidal anti-inflammatory compounds on antioxidant system of human erythrocytes. Exp Toxicol Pathol 51: 397–402

    Article  PubMed  CAS  Google Scholar 

  192. Maffei Facino R, Carini M, Aldini G, Saibene L, Morelli R (1995) Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite. Drug Res 45: 10–17

    Google Scholar 

  193. Zheng SX, Mouithys-Mickalad A, Deby-Dupont GP, Deby CM, Maroulis AP, Labasse AH, Lamy ML, Crielaard JM, Reginster JY, Henrotin YE (2000) In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: effects of HRP- and luminal-dependent chemiluminescence produced by human chondrocytes. Osteoarthritis and Cartilage 8: 419–425

    Article  PubMed  CAS  Google Scholar 

  194. Mouithys-Mickalad AM, Zheng SX, Deby-Dupont GP, Deby CM, Lamy MM, Reginster JY, Henrotin YE (2000) In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radic Res 33: 607–621

    Article  PubMed  CAS  Google Scholar 

  195. Tavares IA, Bishai PM, Bennett A (1995) Activity of nimesulide on constitutive and inducible cyclooxygenases. Drug Res 45: 1–3

    Google Scholar 

  196. Shah AA, Murray FE, Fitzgerald DJ (1999) The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology 38: 19–23

    Article  PubMed  CAS  Google Scholar 

  197. Saeed SA, Afzal MN, Shah BH (1998) Dual effects of nimesulide, a COX-2 inhibitor, in human platelets. Life Sci 63: 1835–1841

    Article  PubMed  CAS  Google Scholar 

  198. Islas Cadena M, Aguirre Banuelos P, Granados Soto V (1999) Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J Pharmacol Toxicol Methods 42: 87–92

    Article  Google Scholar 

  199. Miranda HF, Lopez J, Sierralta F, Correa A, Pinardi G (2001) NSAID antinociception measured in a chemical and thermal assay in mice. Pain Res Manag 6: 190–196

    PubMed  CAS  Google Scholar 

  200. Sandrini G, Tassorelli C, Cecchini AP, Alfonsi E, Nappi G (2002) Effects of nimesulide on nitric oxide-induced hyperalgesia in humans - a neurophysiological study. Eur J Pharmacol 450: 259–262

    Article  PubMed  CAS  Google Scholar 

  201. Lopez R, Llinas MT, Roig F, Salazar FJ (2003) Role of nitric oxide and cyclooxygenase-2 in regulating the renal hemodynamic response to norepinephrine. Am J Physiol Regul Integr Comp Physiol 284: R488–R493

    PubMed  CAS  Google Scholar 

  202. Korolkiewicz RP, Ujda M, Dabkowski J, Ruczynski J, Rekowski P, Petrusewicz J (2003) Differential salutary effects of nonselective and selective COX-2 inhibitors in postoperative ileus in rats. J Surg Res 109: 161–169

    Article  PubMed  CAS  Google Scholar 

  203. Caparroz-Assef SM, Salgueiro-Pagadigorria CL, Bersani-Amado CA, Bracht A, Kelmer-Bracht AM, Ishii-Iwamoto EL (2001) The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem Funct 19: 117–124

    Article  PubMed  CAS  Google Scholar 

  204. Mingatto FE, dos Santos AC, Rodrigues T, Pigoso AA, Uyemura SA, Curti C (2000) Effects of nimesulide and its reduced metabolite on mitochondria. Brit J Pharmacol 131: 1154–1160

    Article  CAS  Google Scholar 

  205. Mingatto FE, Ridrigues T, Pigoso AA, Uyemura SA, Curti C, Santos AC (2002) The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther 303: 601–607

    Article  PubMed  CAS  Google Scholar 

  206. Rainsford KD, Seabrook RW, Spencer S, Hewson AT (2001) Effects of nimesulide and its metabolites or manufacturing intermediates on the viability and growth of the human hepatoma HepG2 cell line. Life Sci 69: 2965–2973

    Article  PubMed  CAS  Google Scholar 

  207. Titos E, Chiang N, Serhan CN, Romano M, Gaya J, Pueyo G, Claria J (1999) Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). Am J Physiol 277: C870–C877

    PubMed  CAS  Google Scholar 

  208. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, Petit CR (2000) The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973–976

    Article  PubMed  CAS  Google Scholar 

  209. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6: 2006–2011

    PubMed  CAS  Google Scholar 

  210. Zhang Z, DuBois RN (2000) Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 118: 1012–1017

    Article  PubMed  CAS  Google Scholar 

  211. Tian G, Yu JP, Luo HS, Yu BP, Yue H, Li JY, Mei Q (2002) Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells. World J Gastroenterol 8: 483–487

    PubMed  CAS  Google Scholar 

  212. Maria DA, Ribeiro OG, Pizzocaro KF, De Franco M, Cabrera WK, Starobinas N, Gallois V, Siqueira M, Seman M, Ibanez OM (2000) Resistance to melanoma metastases in mice selected for high acute inflammatory response. Carcinogenesis 22: 337–342

    Article  Google Scholar 

  213. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-l-methyl-6-phenylimidazo[4,5-ffipyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91: 886–892

    Article  PubMed  CAS  Google Scholar 

  214. Kawamori T, Wakabayashi K (2002) COX-2 and prostanoid receptors: good targets for chemoprevention. J Environ Pathol Toxicol Oncol 21: 149–153

    Article  PubMed  CAS  Google Scholar 

  215. Kubatka P, Kalicka K, Chamilova M, Ahlersova E, Ahlers I, Bojkova B, Adamekova E (2002) Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 49: 255–259

    PubMed  CAS  Google Scholar 

  216. Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K, Hirose M (2003) A cyclooxygenase-2 inhibitor, nimesulide, inhibits post-initiation phase of N-nitrosobis (2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 104: 269–273

    Article  PubMed  CAS  Google Scholar 

  217. Vardar S, Baylas H, Huseyinov A (2003) Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis. J Periodontol 74: 57–63

    Article  PubMed  CAS  Google Scholar 

  218. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S (2002) Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278–284

    Article  PubMed  CAS  Google Scholar 

  219. Denda A, Kitayama W, Murata A, Kishida H, Sasaki Y, Kusuoka O, Tsujiuchi T, Tsutsumi M, Nakae D, Takagi H et al (2002) Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis 23: 245–256

    Article  PubMed  CAS  Google Scholar 

  220. Mukherjee P, Pasinetti GM (2002) Altered gene expression during nimesulide-mediated inhibition of apoptotic death in human chondrocytes. lot J Clin Pract Suppl 128: 20–23

    CAS  Google Scholar 

  221. Wang D, An SJ, Wang WH, McGiff JC, Ferrari NR (2001) CaR-mediated COX-2 expression in primary cultured in TAL cells. Am J Physiol Renal Physiol 281: F658–F654

    PubMed  CAS  Google Scholar 

  222. Kalajdzic T, Faour WH, He QW, Fahmi H, Martel-Pelletier J, Pelletier JP, Di Battista JA (2002)Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferators-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum 46: 494–506

    Article  PubMed  CAS  Google Scholar 

  223. Fahmi H, He Y, Zhang M, Martel-Pelletier J, Pelletier JP, Di Battista JA (2001) Nimesulide reduces interleukin-]beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts. Osteoarthritis Cartilage 9: 332–340

    Article  PubMed  CAS  Google Scholar 

  224. Sharma S, Rastogi S, Gupta V, Rohtagi D, Gulati P (1999) Comparative efficacy and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection. Am J Ther 6: 191–197

    Article  PubMed  CAS  Google Scholar 

  225. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammtory drugs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 158: 33–39

    Article  PubMed  CAS  Google Scholar 

  226. Conforti A, Leone R, Moretti U, Mozzo F, Velo G (2001) Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting fgrom a Northern Italian area. Drug Safety 24: 1081–1090

    Article  PubMed  CAS  Google Scholar 

  227. Macia MA, Carvajal A, del Pozo JG, Vera E, del Pino A (2002) Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 72: 596–597

    PubMed  CAS  Google Scholar 

  228. Villa G (1999) NSAIDs and hepatic reactions. Lancet 353: 846

    Article  PubMed  CAS  Google Scholar 

  229. Chitturi S, Farrell GC (2001) Drug-induced cholestasis. Sem Gastrointest Dis 12: 113–124

    CAS  Google Scholar 

  230. Elmalem E (2000) Nimesulide, clavulanic acid and hepatitis. J Intern Med 248: 168–169

    Article  PubMed  CAS  Google Scholar 

  231. Kanwar AJ, Kaur S, Thami GP (2000) Nimesulide-induced purpura. Dermatology 201: 376

    Article  PubMed  CAS  Google Scholar 

  232. Sanchez-Borges M, Capriles-Hulett A (2000) Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 84: 101–106

    Article  PubMed  CAS  Google Scholar 

  233. Nettis E, Marcandrea M, Ferrannini A, Tursi A (2001) Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema. Immunopharmacol Immunotoxicol 23: 343–354

    Article  PubMed  CAS  Google Scholar 

  234. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, Cocci A, Moretti U, Velo G, Leone R (1999) Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 48: 839–846

    Article  PubMed  CAS  Google Scholar 

  235. Anonymous (1993) Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 186: 164–169

    Article  Google Scholar 

  236. Tursen U, Kaya TI, Kokturk A, Dusmez D (2001) Lichenoid photodermatitis associated with nimesulide. Int J Dermatol 40: 767–768

    Article  PubMed  CAS  Google Scholar 

  237. Sanchez Borges M, Capriles-Hulett A, Caballero-Foneseca F, Perez CR (2001) Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 87: 201–204

    Article  CAS  Google Scholar 

  238. Kanikkannan N, Jackson T, Shaik MS, Singh M (2001) Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay. Eur J Pharm Sci 14: 217–220

    Article  PubMed  CAS  Google Scholar 

  239. Mangalvedhekar SS, Gogtay NJ, Phadke AV, Gore S, Shah JM, Shah SM, Kshirsagar NA (2000) Adverse drug reactions postal survey-bronchial asthma and angioedema with nimesulide. J Assoc Physicians India 48: 548

    PubMed  CAS  Google Scholar 

  240. Llinas MT, Rodriguez F, Moreno C, Salazar FJ (2000) Role of cyclooxygenase-2-derived metabolites and nitric oxide in regulating renal function. Am J Physiol Regul Integr Comp Physiol 279: R1641–R1646

    PubMed  CAS  Google Scholar 

  241. Aisen PS, Schmeidler J, Pasinetti GM (2002) Randomized pilot study of nimesulide treatment of Alzheimer’s disease. Neurology 58: 1050–1054

    Article  PubMed  CAS  Google Scholar 

  242. Food and Drug Administration (USA) Celebrex®(celecoxib capsules). Centre for Drug Evaluation. (CDER, New and Generic Drug Approvals: 1998–2003), NDA Application # 20–998, approval date 12/31/98. Pharmacological Review, part 1–7, posted 6/9/99.http://www.fda.gov/cder/approvallindex.htm (Accessed Dec 2003)

  243. Clemett D, Goa KL (2000) Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59: 957–980

    Article  PubMed  CAS  Google Scholar 

  244. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 445- (4-methylpheny1)-3-(trifluoromethyl)-/H-pyrazol-1-yllbenzene sulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347–1365

    Article  PubMed  CAS  Google Scholar 

  245. Hamilton LC, Mitchell JA, Tomlinson AM, Warner TD (1999) Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal anti-inflammatory drug efficacy. FASEB J 13: 245–251

    PubMed  CAS  Google Scholar 

  246. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson (1998) Pharmacological analysis of cycloxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313–13318

    Article  PubMed  CAS  Google Scholar 

  247. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 339: 607–614

    Article  PubMed  CAS  Google Scholar 

  248. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib. A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225–242

    Article  PubMed  CAS  Google Scholar 

  249. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxgyenase-II inhibitor. J Pharmacol Exp Ther 293: 453–459

    PubMed  CAS  Google Scholar 

  250. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL (1999) Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metabolism and Disposition 27: 1133–1142

    PubMed  CAS  Google Scholar 

  251. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS et al (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metabolism and Disposition 28: 514–521

    PubMed  CAS  Google Scholar 

  252. Paulson SK, Zhang JY, Jessen SM, Lawal Y, Liu NW, Dudkowski CM, Wang YF, Change M, Yang D, Findlay JW et al (2000) Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica 30: 731–744

    Article  PubMed  CAS  Google Scholar 

  253. Zhang JY, Wang Y, Dudkowski C, Yang D, Chang M, Yuan J, Paulson SK, Breau AP (2000) Characterization of metabolites of celecoxib in rabbits by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 35: 1259–1270

    Article  PubMed  CAS  Google Scholar 

  254. Tibble JA, Sigthorsson G, Forster R, Bjarnason I (2000) Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 35: 802–807

    Article  PubMed  CAS  Google Scholar 

  255. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 297: 638–645

    PubMed  CAS  Google Scholar 

  256. Tanaka A, Hase S, Miyazawa T, Takeuchi K (2002) Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300: 754–761

    Article  PubMed  CAS  Google Scholar 

  257. O’Beirne JP, Cairns SR (2001) Drug points: Cholestatic hepatitis in association with celecoxib. BMJ 323: 23

    Article  PubMed  Google Scholar 

  258. Pinheiro RM, Calixto JB (2002) Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 51: 603–610

    Article  PubMed  CAS  Google Scholar 

  259. Cuzzocrea S, Mazzon E, Sautebin L, Dugo L, Serraino I, De Sarro A, Caputi AP (2002) Protective effects of celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem Pharmacol 63: 785–795

    Article  PubMed  CAS  Google Scholar 

  260. Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, Bakhle YS (2002) Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137: 837–844

    Article  PubMed  CAS  Google Scholar 

  261. Torres-Lopez JE, Ortiz MI, Castaneda-Hernandez G, Alonso-Lopez R, Asomoza-Espinosa R, Granados-Soto V (2002) Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 70: 1669–1676

    Article  PubMed  CAS  Google Scholar 

  262. Shin MC, Jang MH, Chang HK, Kim YJ, Kim EH, Kim CJ (2003) Modulation of cyclooxygenase-2 on glycine-and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 59: 251–256

    Article  PubMed  CAS  Google Scholar 

  263. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemoprotective activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409–412

    PubMed  CAS  Google Scholar 

  264. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventative and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040–5044

    PubMed  CAS  Google Scholar 

  265. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7: 1377–1381

    PubMed  CAS  Google Scholar 

  266. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60: 5599–5602

    PubMed  CAS  Google Scholar 

  267. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742–2744

    PubMed  CAS  Google Scholar 

  268. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62: 165–170

    PubMed  CAS  Google Scholar 

  269. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and incudes apoptosis in anagiogenic endothelial cells in vivo . Cancer Res 62: 625–631

    PubMed  CAS  Google Scholar 

  270. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O’Reilly T, Wotherspoon G, Winter J, Green J, Urban L (2002) A rat model of bone cancer pain. Pain 96: 129–140

    Article  PubMed  CAS  Google Scholar 

  271. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS (2002) Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 138: 751–755

    Article  PubMed  CAS  Google Scholar 

  272. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC (2002) Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Letters 184: 7–12

    Article  PubMed  CAS  Google Scholar 

  273. Wenger FA, Kilian M, Bisevac M, Khodadayan C, von Seebach M, Schimke I, Gush H, Muller JM (2002) Effects of celebrex and zyflo on liver metastasis and lipid peroxidation in pancreatic cancer in Syrian hamsters. Clin Exp Metastasis 19: 681–687

    Article  PubMed  CAS  Google Scholar 

  274. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405–5407

    PubMed  CAS  Google Scholar 

  275. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side-effect of CPT-11. Cancer Res 62: 5778–5784

    PubMed  CAS  Google Scholar 

  276. Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC, Hall WA, Trajkovic D, Khan KN, Tripp CS (2003) Selective cycloxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol 148: 211–223

    Article  PubMed  CAS  Google Scholar 

  277. Neiderberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NThcB. FASEB J 15: 1622–1624

    Google Scholar 

  278. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL (2002) Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 62: 6706–6711

    PubMed  CAS  Google Scholar 

  279. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96–102

    Article  PubMed  CAS  Google Scholar 

  280. Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioural impairments in the rat. J Neurosci Res 68: 337–343

    Article  PubMed  CAS  Google Scholar 

  281. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966: 245–252

    Article  PubMed  CAS  Google Scholar 

  282. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771–778

    Article  PubMed  CAS  Google Scholar 

  283. Appel GB (2001) COX-2 inhibitors and the kidney. Clin Exp Rheumatol 19 (Suppl 25): S37–S40

    PubMed  CAS  Google Scholar 

  284. Boyd IW, Mathew TH, Thomas MC (2000) COX-2 inhibitors and renal failure: the triple whammy revisited. Medical Journal of Australia 173: 274

    PubMed  CAS  Google Scholar 

  285. Brater DC, Harris C, Redfern JS, Benz BJ (2001) Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1–15

    Article  PubMed  CAS  Google Scholar 

  286. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ et al (2000) Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Int Med 133: 1–9

    PubMed  CAS  Google Scholar 

  287. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM (2001) Cyclooxygenase-2- specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Amer J Ther 8: 85–95

    Article  CAS  Google Scholar 

  288. Kiyataka M, Rich KA, Ingram M, Yamamoto T, Bing RJ (2002) Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension 39: 785–789

    Article  Google Scholar 

  289. Hocherl K, Wolf K, Castrop H, Ittner KP, Bucher M, Kees F, Grobecker HF, Kurtz A (2001) Renocortical expression of renin and of cyclooxygenase-2 in response to angiotensin II AT1 receptor blockade is closely coordinated but not causally linked. Pflugers Arch 442: 821–827

    Article  PubMed  CAS  Google Scholar 

  290. Muscara MN, Vergnolle N, Lobren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL (2000) Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 129: 1423–1430

    Article  PubMed  CAS  Google Scholar 

  291. Ozturk H, Ozdemir E, Otcu S, Buyukbayram H, Ihsan Dokucu A (2002) Renal effects on a solitary kidney of specific inhibition of cyclooxygenase-2 after 24 h of complete ureteric obstruction in rats. Urol Res 30: 223–226

    Article  PubMed  CAS  Google Scholar 

  292. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66: 76–84

    Article  PubMed  CAS  Google Scholar 

  293. Kitahara M, Eitner F, Ostendorf T, Kunter U, Janssen U, Westenfeld R, Matsui K, Kerjaschki D, Floege J (2002) Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 13: 1261–1270

    PubMed  CAS  Google Scholar 

  294. Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, Pise-Masison CA, Pohl LR (2001) A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 14: 1620–1628

    Article  PubMed  CAS  Google Scholar 

  295. Rainsford KD (1991) Uncoupling the toxicological morass in the development of new antirheumatic drugs-is there any hope? Br J Rheumatol 30: 161–163

    Article  PubMed  CAS  Google Scholar 

  296. Rainsford KD (1989) Gastrointestinal side-effects. In: CY Chang, AJ Lewis (eds): Pharmacological Methods in the Control of Inflammation. Alan R Liss, New York, 343–362

    Google Scholar 

  297. Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K (2002) Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 303: 503–509

    Article  PubMed  CAS  Google Scholar 

  298. Kato S, Takeuchi K (2002) Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn J Pharmacol 89: 1–6

    Article  PubMed  CAS  Google Scholar 

  299. Ma L, del Soldato P, Wallace JL (2002) Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA 99: 13243–13247

    Article  PubMed  CAS  Google Scholar 

  300. Tibble J, Sigthorsson G, Caldwell C, Palmer RH, Bjarnason I (2001) Effects of NSAIDs on crypoprobe-induced gastric ulcer healing in rats. Aliment Pharmacol Ther 15: 2001–2008

    Article  PubMed  CAS  Google Scholar 

  301. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, Sautebin L, Caputi AP (2001) Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 431: 91–102

    Article  PubMed  CAS  Google Scholar 

  302. Ostensen M (2001) Drugs in pregnancy. Rheumatological disorders. Best Pract Res Clin Obstet Gynecol 15: 953–969

    Article  CAS  Google Scholar 

  303. Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK (2001) Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 142: 3198–3206

    Article  PubMed  CAS  Google Scholar 

  304. Takahashi Y, Roman C, Chemtob S, Tse MM, Lin E, Heymann MA, Clyman RI (2000) Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 278: R1496–R1505

    CAS  Google Scholar 

  305. Ozaki N, Beharry K, Nishihara KC, Akmal Y, Ang JG, Modanlou HD (2002) Differential regulation of prostacyclin and thromboxane by dexamethasone and celecoxib during oxidative stress in newborn rabbits. Prostaglandins Other Lipid Mediat 70: 61–78

    Article  PubMed  CAS  Google Scholar 

  306. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY et al (2000) 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43: 775–777

    Article  PubMed  CAS  Google Scholar 

  307. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K (2000) N-[[(5-methy1–3-phenylisoxazol 4 yl) phenyl]sulfonyl]propan-amide, sodium salt, paracoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43: 1661–1663

    Article  PubMed  CAS  Google Scholar 

  308. US Food and Drug Adminstration, Centre for Drug Evaluation and Research (2002) Bextra (valdecoxib) tablets. Company: G. D. Searle and Co. Application No.: 21–341. Approval Date: 11/16/01http://www.fda.goy/cder/foi/nda/2001/21-341_Bextra.htm(Accessed 25/10/2002)

  309. Benson W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, Recker DP (2002) Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 41: 1008–1016

    Article  Google Scholar 

  310. Makarowski W, Zhao WW, Bevirt T, Recker DP (2002) Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis and Cartilage 10: 290–296

    Article  PubMed  CAS  Google Scholar 

  311. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM (2002) Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 14: 1101–1111

    Article  PubMed  CAS  Google Scholar 

  312. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Kent JD (2003) A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 18: 125–132

    Article  PubMed  CAS  Google Scholar 

  313. Strand V, Hochberg MC (2002) The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis and Rheumatism 47: 349–355

    Article  PubMed  CAS  Google Scholar 

  314. White WB, Verburg KM, Whelton A (2003) The COX-2 specific inhibitor, valdecoxib, is not associated with an increased risk of cardiovascular thrombotic events in arthritis patients

    Google Scholar 

  315. Prasit P, Wang Z, Brideau C, Chan C-C, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY et al (1999) The discovery of rofecoxib, (MK 966, VIOXX, 4∀-(4’- methylsulfonylpheny1)-3-pheny1–2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorganic and Medicinal Chemistry Letters 9: 1773–1778

    Article  PubMed  CAS  Google Scholar 

  316. Scott LJ, Lamb HM (1999) Rofecoxib: new drug profile. Drugs 58: 499–506

    Article  PubMed  CAS  Google Scholar 

  317. Ahuja N, Singla AK, Singh A, Singh B (2003) Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 55: 859–894

    Article  PubMed  CAS  Google Scholar 

  318. Food and Drug Adminstration (USA): Vioxx®(rofecoxib). Centre for Drug Evaluation (CDER, New and Generic Drug Approvals: 1998–2003), NDA Application # 21–042, approval date 5/20/99. Pharmacological Review posted 4/17/00.http://www.fda.gov/cder/approval/index.htm(Accessed Dec 2003)

  319. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ether D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY et al (1999) Rofecoxib (Vioxx, MK-0966); 4-(4’-methylsulfonylpheny1)- 3-pheny1–2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551–560

    PubMed  CAS  Google Scholar 

  320. Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Leger S, Roy P et al (2000) Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor reofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett 10: 2683–2686

    Article  PubMed  CAS  Google Scholar 

  321. Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA (2000) A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX®), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 40: 1509–1515

    PubMed  CAS  Google Scholar 

  322. Feldman M, McMahon AT (2000) Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 132: 134–143

    PubMed  CAS  Google Scholar 

  323. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE (1999) Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13: 761–767

    Article  PubMed  CAS  Google Scholar 

  324. Bombardier C, Lain L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528

    Article  PubMed  CAS  Google Scholar 

  325. Depré M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ (2000) Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 56: 167–174

    Article  PubMed  Google Scholar 

  326. Schoenfeld P (2001) An evidence-based approach to the gastrointestinal safety profile of COX-2 selective ani-inflammatories. Gastroenterology Clinics of North America 30: 1027–1044

    Article  PubMed  CAS  Google Scholar 

  327. Daniels B, Gertz B, Morrison B, Seidenberg B (2003) Renal safety profile of rofecoxib, a spe-cific inhibitor of COX-2, in controlled clinical trials. European League of Rheumatology Congress (EULAR), Lisbon, Portugal

    Google Scholar 

  328. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A (1999) Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Letters 457: 475–477

    Article  PubMed  CAS  Google Scholar 

  329. Layton D, Riley J, Wilton LV, Shakir SAW (2003) Safety profile of Rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 55: 166–174

    Article  PubMed  CAS  Google Scholar 

  330. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B (2000) Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis and Rheumatism 43: 978–987

    Article  PubMed  CAS  Google Scholar 

  331. Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T et al (2001) Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stble isotope-labeling techniques. Drug Metab Dispos 29: 1614–1628

    PubMed  CAS  Google Scholar 

  332. Halpin RA, Geer LA, Zhang Kem Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP (2000) The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab Dispos 28: 1244–1254

    PubMed  CAS  Google Scholar 

  333. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan Gertz BJ, Fitzgerald GA (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735–741

    PubMed  CAS  Google Scholar 

  334. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao P, Quan H, Bolognese JA, Simon TJ (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assn 282: 1929–1933

    Article  CAS  Google Scholar 

  335. Strand V, Hochberg MCC (2002) The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis and Rheumatism 47: 349–355

    Article  PubMed  CAS  Google Scholar 

  336. McAdam BF, Catella-Lawson F, Maradini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2. The human pharmacology of a selective inhibitor of COX-2. Proc Natal Acad Sci USA 96: 272–277

    Article  Google Scholar 

  337. Niederberger E, Tegeder I, Schafer C, Seegel M, Grosch S, Geisslinger G (2003) Opposite effects of rofecoxib on nuclear factor kappaB and activating protein-1 activation. J Pharmacol Exp Ther 304: 1153–1160

    Article  PubMed  CAS  Google Scholar 

  338. Callejas NA, Fernandez-Martinez A, Castrillo A, Bosca L, Martin-Sanz P (2003) Selective inhibitors of cyclooxygenase-2 delay the activation of the nuclear factor kappa B and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. Mol Pharmacol 63: 671–677

    Article  PubMed  CAS  Google Scholar 

  339. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM, Evans JF (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733–1740

    PubMed  CAS  Google Scholar 

  340. Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, Lopez-Munoz FJ (2002) Involvement of peripheral cycloxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Phannacol 54: 405–412

    Article  CAS  Google Scholar 

  341. Sandrini M, Vitale G, Pini LA (2002) Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res 51: 154–159

    Article  PubMed  CAS  Google Scholar 

  342. El-Shenawy SM, Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS (2002) Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol Res 46: 235–243

    Article  PubMed  CAS  Google Scholar 

  343. Hutchins B, Patel H, Spears R (2002) Attenution of pro-inflammatory neuropeptide levels produced by a cyclooxygenase-2 inhibitor in an animal model of chronic temporomandibular joint inflammation. J Orofac Pain 16: 312–316

    PubMed  Google Scholar 

  344. Kalgutkar AS, Zhao Z (2001) Discovery and design of selective cyuclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets 2: 79–106

    Article  PubMed  CAS  Google Scholar 

  345. Dicker AP, Williams TL, Grant DS (2001) Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24: 438–442

    Article  PubMed  CAS  Google Scholar 

  346. Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Schuppan D, Drozdowicz D, Ptak A, Pawlik M, Nakamura T, Hahn EG (2000) Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol 51: 751–773

    PubMed  CAS  Google Scholar 

  347. Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry L, Sambrano J, Godoy A, Rocaspana A (2001) Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 46: 779–784

    Article  PubMed  CAS  Google Scholar 

  348. Pajdo R, Brzozowski T, Konturek PC, Kwiecien S, Konturek SJ, Sliwowski Z, Pawlik M, Ptak A, Drozdowicz D, Hahn EG (2001) Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves. Eur J Pharmacol 427: 263–276

    Article  PubMed  CAS  Google Scholar 

  349. Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15: 1–9

    Article  PubMed  CAS  Google Scholar 

  350. Simon AM, Manigrasso MB, O’Connor JP (2002) Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17: 977–978

    Article  Google Scholar 

  351. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL (2002) COX-2 selective NSAID decreases bone in growth in vivo. J Orthop Res 20: 1164–1169

    Article  CAS  Google Scholar 

  352. Cochrane DJ, Jarvis B, Keating GM (2002) Etoricoxib. Drugs 62: 2637–2651

    Article  PubMed  CAS  Google Scholar 

  353. Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret J-P, Friesen RW, Gordon R, Greig G et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296: 558–566

    PubMed  CAS  Google Scholar 

  354. Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasseter KC, Hunt et al (2003) Single-and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 43: 268–276

    Article  PubMed  CAS  Google Scholar 

  355. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, Detora L, Curtis S, Geissler L, Gertz BJ (2002) Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 41: 1052–1061

    Article  PubMed  CAS  Google Scholar 

  356. Matsumoto AK, Melian A, Mandel DR, Mcllwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S (2002) A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 29: 1623–1630

    PubMed  CAS  Google Scholar 

  357. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, Zhao PL, Ridgers DB, McCormick CL, Lee M, Lines CR, Gertz BJ (2002) A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 3: 2–10

    Article  Google Scholar 

  358. Sorbera LA, Castaner J, Bayes M, Silvestre JS (2002) Lumiracoxib. Drugs of the Future 27: 740–747

    Article  CAS  Google Scholar 

  359. Reynolds C, Scott G, Looby M, Milosavljev S, Huff JP, Ruff DA, Rordorf C (2003) Pharmacokinetics of lumiracoxib in synovial fluid and plasma of patients with rheumatoid arthritis. European Assoc. Clinical Pharmacology and Therapeutics (EACPT), Istanbul; P-195 (Abstr)

    Google Scholar 

  360. Scott G, Branson J, Miloszvljev S, Rordorf C, Haraoui B, Ouellet J-P, Schell E (2003) Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Ann Rheum Dis 62 (Suppl 1): FRI235 (Abstr)

    Google Scholar 

  361. Bonner J, Branson J, Milosavljev S, Rordorf C, Scott G (2003) Co-administration of lumiracoxib and warfarin does not alter the pharmacokinetic profile of R- or S-warfarin. Ann Rheum Dis 62 (Suppl 1): FRI0225 (Abstr)

    Google Scholar 

  362. Hartman S, Scott G, Rordorf C, Campesrini J, Branson J, Keller U (2003) Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. European Assoc. Clinical Pharmacology and Therapeutics (EACPT), Istanbul; P-199 (Abstr)

    Google Scholar 

  363. Wilding IR, Connor AL, Carpenter P, Rordorf C, Branson J, Milosavljev S, Scott G (2003) Lumiracoxib shows similar bioavailability at different sites in the gastrointestinal tract. European Assoc. Clinical Pharmacology and Therapeutics (EACPT), Istanbul; P-196 (Abstr)

    Google Scholar 

  364. Grifka J, Zacher J, Brown J, Seriolo B, Lee A, Moore A, Gimona A (2003) Lumiracoxib is effective and well tolerated in patients with osteothritis of the hand: a randmomized placebo-controlled trial. Ann Rheum Dis 62 (Suppl 1): FRI0222 (Abstr)

    Google Scholar 

  365. Benevolenskaya L, Tüzün S, Hagin E, Moore A, Gimona A (2003) Lumiracoxib is effective in relieving symptoms of osteoarthritis of the hip or knee after 4 weeks of treatment: results from a randomized placebo-controlled trial. Ann Rheum Dis 62 (Suppl 1): FRI0246 (Abstr)

    Google Scholar 

  366. Fleischman R, Sheldon E, Maldonado Cocco J, Yu S, Dutta D, Usiskin K (2003) A prospective randomized 13-week study revaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee. Ann Rheum Dis 62 (Suppl 1): FRI0233 (Abstr)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK

    K. D. Rainsford

Authors
  1. K. D. Rainsford
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pulmonary Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397, Biberach a. d. Riss, Germany

    Michel Pairet

  2. Department Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397, Biberach a. d. Riss, Germany

    Joanne van Ryn

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Rainsford, K.D. (2004). Pharmacology and toxicology of COX-2 inhibitors. In: Pairet, M., van Ryn, J. (eds) COX-2 Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7879-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7879-1_4

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9607-8

  • Online ISBN: 978-3-0348-7879-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation